Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera April 28, 2026
Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology April 21, 2026
Boehringer Ingelheim and Zai Lab announce collaboration on DLL3‑targeting T‑Cell Engager and ADC combination in SCLC and other Neuroendocrine Carcinomas April 21, 2026
IASO Bio Establishes International Partnership with Instituto Butantan to Develop Innovative Therapy for Hematological Cancer April 21, 2026
Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development April 21, 2026
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement April 21, 2026
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Ph 2 Sarcoma Trial of STC‑15 April 21, 2026
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform April 21, 2026
CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Gen Dual-Payload ADCs April 21, 2026
C4 Therapeutics and Roche Enter New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) April 15, 2026
Adagene and Incyte to Evaluate Muzastotug (ADG126) in Combination with INCA33890 in Patients with MSS CRC April 15, 2026
Oxford BioTherapeutics Enters Strategic Collaboration with BMS to Discover and Develop Next-Gen T-cell Engagers for Solid Tumours April 15, 2026
Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors April 15, 2026
Wugen Selected for US FDA CMC Development and Readiness Pilot Program to Support Manufacturing Readiness of Soficabtagene Geleucel April 15, 2026
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Ph 3 Trial of Novel Telomere-Targeting Anticancer Therapy April 15, 2026
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer April 15, 2026
Boston Oncology CGT Holding to license Xuanzhu Biopharmaceutical’s Bireociclib and Dirozalkib April 15, 2026
Gilead to Acquire Tubulis Adding ADC and Next Gen Platform to Further Strengthen Oncology Pipeline April 15, 2026
Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Ph 1b/2 trial of obrixtamig with pumitamig in ES-SCLC April 15, 2026
Oricell Therapeutics Closes $110 Million Pre-IPO Financing for Global Development of Solid Tumor CAR-T Therapies April 15, 2026
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement with Amgen to Evaluate Zocilurtatug Pelitecan in Combination with Imdelltra April 7, 2026
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Novel ADC Payload Targeting RNA Splicing April 7, 2026
